<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033390/" ref="ordinalpos=1159&amp;ncbi_uid=2757592&amp;link_uid=PMC3033390" image-link="/pmc/articles/PMC3033390/figure/pone-0016556-g007/" class="imagepopup">Figure 7. Schematic model of BBR <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span>..  From: Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis. </a></div><br /><div class="p4l_captionBody">BBR inhibits mitochondria function and decrease intracellular ATP. This leads to a reduction in gluconeogenic and lipogenic transcription factors (FoxO1, SREBP1, and ChREBP). As a result, expression of gluconeogenic genes (PEPCK and G6Pase) and lipogenic gene (FAS) are decreased. These molecular changes represent a signaling pathway for improvement of fasting glucose and liver steatosis in the BBR-treated diabetic rats.</div></div>